CVA Family Office’s Xenon Pharmaceuticals XENE Stock Holding History

CVA Family Office’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Hold	33	–	–	﹤0.01%	1520
2026 Q1	$1.92K	Hold	33	–	–	﹤0.01%	1536
2025 Q4	$1.48K	Hold	33	–	–	﹤0.01%	1036
2025 Q3	$1.32K	Hold	33	–	–	﹤0.01%	1069
2025 Q2	$1.03K	Hold	33	–	–	﹤0.01%	1094
2025 Q1	$1.11K	Hold	33	–	–	﹤0.01%	1088
2024 Q4	$1.29K	Hold	33	–	–	﹤0.01%	1050
2024 Q3	$1.3K	Hold	33	–	–	﹤0.01%	1040
2024 Q2	$1.29K	Sell	33 -20	-38%	-$799	﹤0.01%	1030
2024 Q1	$2.28K	Buy	53 +20	+61%	+$920	﹤0.01%	919
2023 Q4	$1.52K	Buy	+33	New	+$1.17K	﹤0.01%	933

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CVA Family Office's XENE Position: Q2 2026 in Review

CVA Family Office held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 33 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

CVA Family Office first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.28K in Q1 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

CVA Family Office held 33 shares of Xenon Pharmaceuticals worth $1.99K as of Q2 2026.
CVA Family Office left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1520 holding.
CVA Family Office first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
CVA Family Office's Xenon Pharmaceuticals position peaked at $2.28K in Q1 2024.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.